[Pharmacology of uxepam].
A new daytime tranquilizer uxepam--1-methyl-4-carbamoyl-5-phenyl-7-chloro-1,3,4,5-tetrahydro-2H-1, 4-benzodiazepine-2-on (RGH-3331) administered to animals removes emotional-behavioral abnormalities under conflict situation, reduces aggressiveness induced by electric and painful stimulation, prevents convulsions induced by corasole and electric shock, prolongs the hypnotic effect of hexenal. When applied in high doses the drug suppresses the avoidance reflex, orienting-research behavior and motor activity, disturbs movement coordination. Within wide dosage range uxepam potentiates the summation activity in the central nervous system. As regards anxiolytic activity, the drug does not yield to diazepam and compares very favourably with chlordiazepoxide. The sedative and myorelaxant effects displayed by uxepam are insignificant. The data obtained make it possible to attribute uxepam to daytime tranquilizers.
D000374:Aggression / Q000187:drug effects; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology* / Q000633:toxicity; D001362:Avoidance Learning / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000494:pharmacology* / Q000633:toxicity; D003214:Conditioning, Classical / Q000187:drug effects; D003220:Conflict, Psychological; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors; D011817:Rabbits; D051381:Rats
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D001569:Benzodiazepines; C039647:uxepam; D010433:Pentylenetetrazole
Farmakologiia uksepama.